Brief: Amicus Therapeutics Q2 Revenue USD 126.7 Million Vs. IBES Estimate USD 121.2 Million
Aug 08 (Reuters) - Amicus Therapeutics Q2 EPS USD -0.05. * Q2 operating expenses USD 100.4 million * Q2 adjusted operating expenses USD 82.1 million * Q2 net income USD -15.7 million
Recent news on Amicus Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Amicus Q4 revenue beats estimates